Literature DB >> 31541411

Drug-Induced Urolithiasis in Pediatric Patients.

Maria Chiara Sighinolfi1, Ahmed Eissa2,3, Luigi Bevilacqua2, Ahmed Zoeir2,3, Silvia Ciarlariello2, Elena Morini2, Stefano Puliatti2, Viviana Durante4, Pier Luca Ceccarelli4, Salvatore Micali2, Giampaolo Bianchi2, Bernardo Rocco2.   

Abstract

Drug-induced nephrolithiasis is a rare condition in children. The involved drugs may be divided into two different categories according to the mechanism involved in calculi formation. The first one includes poorly soluble drugs that favor the crystallization and calculi formation. The second category includes drugs that enhance calculi formation through their metabolic effects. The diagnosis of these specific calculi depends on a detailed medical history, associated comorbidities and the patient's history of drug consumption. There are several risk factors associated with drug-induced stones, such as high dose of consumed drugs and long duration of treatment. Moreover, there are some specific risk factors, including urinary pH and the amount of fluid consumed by children. There are limited data regarding pediatric lithogenic drugs, and hence, our aim was to perform a comprehensive review of the literature to summarize these drugs and identify the possible mechanisms involved in calculi formation and discuss the management and preventive measures for these calculi.

Entities:  

Mesh:

Year:  2019        PMID: 31541411     DOI: 10.1007/s40272-019-00355-5

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  120 in total

1.  Urine stone formation during treatment with zonisamide.

Authors: 
Journal:  Brain Dev       Date:  2000-10       Impact factor: 1.961

2.  Nephrocalcinosis in preterm babies.

Authors:  A Narendra; M P White; H A Rolton; Z I Alloub; G Wilkinson; J H McColl; J Beattie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

3.  Possible function of urinary pH and citrate on the ceftriaxone-induced nephrolithiasis.

Authors:  Xiaoming Cong; Xiaojian Gu; Xizhao Sun; Benxiang Ning; Luming Shen
Journal:  Urology       Date:  2013-11-12       Impact factor: 2.649

4.  Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: A prospective study in 154 children.

Authors:  L Ustyol; M D Bulut; K Agengin; K A Bala; A Yavuz; A Bora; K Demiroren; M Dogan
Journal:  Hum Exp Toxicol       Date:  2016-07-10       Impact factor: 2.903

5.  Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus.

Authors:  C E Stafstrom; H E Gilmore; P S Kurtin
Journal:  Pediatr Neurol       Date:  1992 May-Jun       Impact factor: 3.372

6.  Felbamate urolithiasis.

Authors:  S P Sparagana; W R Strand; R C Adams
Journal:  Epilepsia       Date:  2001-05       Impact factor: 5.864

7.  Urolithiasis in pediatric patients with acute lymphoblastic leukemia.

Authors:  S C Howard; S D Kaplan; B I Razzouk; G K Rivera; J T Sandlund; R C Ribeiro; J E Rubnitz; A J Gajjar; W Ke; M L Hancock; J P Skoch; S Roy; M Hudson; C-H Pui
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

Review 8.  Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.

Authors:  Yifan Zhang; Benxiang Ning; Huaijun Zhu; Xiaoming Cong; Leqing Zhou; Qiang Wang; Liming Zhang; Xizhao Sun
Journal:  Int Urol Nephrol       Date:  2016-04-28       Impact factor: 2.370

9.  Zonisamide and renal calculi in patients with epilepsy: how big an issue?

Authors:  Stephen Wroe
Journal:  Curr Med Res Opin       Date:  2007-08       Impact factor: 2.580

10.  Zonisamide Induces Crystalluria without Urinary pH Changes in Children and Young Adults.

Authors:  Tohshin Go
Journal:  ISRN Neurol       Date:  2013-09-19
View more
  1 in total

Review 1.  Animal models of naturally occurring stone disease.

Authors:  Ashley Alford; Eva Furrow; Michael Borofsky; Jody Lulich
Journal:  Nat Rev Urol       Date:  2020-11-06       Impact factor: 16.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.